Cecilia Jones Sells 1,780 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 1,780 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $59,701.20. Following the completion of the sale, the chief financial officer now owns 30,049 shares of the company's stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Agios Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ AGIO traded down $0.18 during mid-day trading on Friday, reaching $33.47. 489,988 shares of the company were exchanged, compared to its average volume of 651,989. The company's 50-day simple moving average is $31.27 and its 200-day simple moving average is $32.11. The stock has a market capitalization of $1.94 billion, a P/E ratio of 2.98 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. As a group, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $33,000. GF Fund Management CO. LTD. bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $39,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at about $40,000. CWM LLC increased its holdings in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares during the period. Finally, Sterling Capital Management LLC increased its holdings in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares during the period.

Analysts Set New Price Targets

AGIO has been the subject of a number of recent analyst reports. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $58.60.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.